Author: admin

“Vagus Nerve Stimulators Market”

(Albany, USA) DelveInsight’s Vagus Nerve Stimulators Market Insights report provides the current and forecast market, upcoming device innovation, individual leading companies market shares, challenges, market drivers, barriers, and trends, and key Vagus Nerve Stimulators companies in the market.

As per DelveInsight analysis, the Vagus Nerve Stimulators Market is witnessing a surge primarily due to the rising prevalence of neurological diseases, the increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications, technological advancements leading to the development of new products such as non-invasive Vagus Nerve Stimulation devices, and others.

Request for sample report @ Vagus Nerve Stimulators Market Insights

Key Takeaways from the Global Vagus Nerve Stimulators Market

• According to DelveInsight analysis, North America is anticipated to dominate the global Vagus Nerve Stimulators market during the forecast period.
• The leading Vagus Nerve Stimulators companies such as LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH, and others are currently dominating the Vagus Nerve Stimulators market.
• In February 2023, LivaNova PLC, a market-leading medical technology and innovation company, launched SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to provide VNS Therapy for the treatment of drug-resistant epilepsy.
• In December 2022, electroCore, Inc., a commercial stage bioelectronic company, announced the launch of a new wellness product offering called Truvaga for customers residing in the U.S.
• In August 2021, the FDA approved the MicroTransponder Vivistim Paired VNS System, a one-of-its-kind, drug rehabilitation system with the intention to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
• In March 2020, LivaNova received the CE Mark approval for their Vagus Nerve Stimulation VNS Therapy® System, Symmetry™ for difficult-to-treat depression.

For more insights about the Vagus Nerve Stimulators market; download the snapshot of the key highlights entailed in the Vagus Nerve Stimulators Market Report

Vagus Nerve Stimulators

A Vagus Nerve Stimulator is a pacemaker-like device that comes with an implantable programmable generator that is implanted in the chest wall and delivers electrical impulses to the vagus nerve in the neck thereby stimulating the vagus nerve and providing relief to patients.

The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Europe, new non-invasive vagus nerve stimulation devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.

Vagus Nerve Stimulators Market Insights

North America is estimated to account for the largest share in the Vagus Nerve Stimulation (VNS) devices market among all the regions. The key driving factors of the North America Vagus Nerve Stimulators market are the high prevalence of epilepsy, depression in the region, increasing disposable income, rising investments, and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region is expected to establish the dominance of the North American Vagus Nerve Stimulation (VNS) devices market in the overall global landscape.

Furthermore, advanced product launches and commercialization agreements among the key VNS companies are further expected to fuel the Vagus Nerve Stimulators market. For instance, in August 2021, the FDA approved drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms the first-of-its-kind Vagus Nerve Stimulation device the MicroTransponder Vivistim Paired VNS System. Thus, the interplay of all the aforementioned factors is likely to fuel the Vagus Nerve Stimulators market growth in the United States during the forecast period.

For further information about the scenario of the Vagus Nerve Stimulators market in other geographies, visit Vagus Nerve Stimulators Market

Vagus Nerve Stimulators Market Dynamics

The Vagus Nerve Stimulators market is experiencing an increase in product demand for a variety of reasons, with one of the key reasons being the rising prevalence of neurological disorders. Moreover, with more positive results being reported concerning the VNS therapy, more research is being conducted on different disease areas, which may further expand the application of Vagus Nerve Stimulation devices in the coming years. For instance, several studies are ongoing in studying the effects of VNS on tinnitus, irritable bowel syndrome, and chronic pain, among other indications. This further presents an opportunity for making significant headway in the Vagus Nerve Stimulators market in the near future.

However, procedure-related complications and the high cost of these devices may be confining factors for the Vagus Nerve Stimulators market growth.

Get a sneak peek at the Vagus Nerve Stimulators market dynamics @ Vagus Nerve Stimulators Market Dynamics Analysis

Scope of the Vagus Nerve Stimulators Market Report

• Coverage: Global
• Study Period: 2022-2030
• VNS Market Segmentation By Product Type- Invasive Vagus Nerve Stimulation Devices and Non-Invasive Vagus Nerve Stimulation Devices
• VNS Market Segmentation by Application- Migraine, Epilepsy, Depression, and Others
• VNS Market Segmentation By End-User – Hospitals, Specialty Clinics, and Others
• VNS Market Segmentation By Geography – North America, Europe, Asia-Pacific, and Rest of World
• Key Vagus Nerve Stimulators Companies – LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH, and others.
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
• DelveInsight Analysis: The Vagus Nerve Stimulators market is expected to grow at a CAGR of 9.06% during the forecast period (2024-30).

Request to know more about Vagus Nerve Stimulators products and mechanism @ Vagus Nerve Stimulation Companies

Table of Contents

1. Vagus Nerve Stimulators Market Report Introduction

2. Vagus Nerve Stimulators Market Executive summary

3. Regulatory and Patent Analysis

4. Vagus Nerve Stimulators Market Key Factors Analysis

5. Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Vagus Nerve Stimulators Market

7. Vagus Nerve Stimulators Market Layout

8. Vagus Nerve Stimulators Global Company Share Analysis – Key 3-5 Companies

9. Vagus Nerve Stimulators Market Company and Product Profiles

10. Project Approach

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vagus Nerve Stimulators Market is Expected to Witness Positive Growth With A CAGR of 9.06% by 2030, estimates DelveInsight

“Global mRNA-based Vaccines and Therapeutics Market”

(Albany, USA) DelveInsight’s Global mRNA-based Vaccines and Therapeutics Market Insights report includes a comprehensive understanding of current treatment practices, emerging global mRNA-based vaccines and therapeutics, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Significant developments have been made in mRNA therapy over the past several decades. Many monotherapies and combinations are in trial. Companies are diligently working toward the development of novel treatments. Key players such as BioNTech SE, ModernaTX, CureVac, Sanofi, and others are some of the major players that are going to boost the global mRNA-based vaccines and therapeutics market dynamics in the coming years.

Key Takeaways from the Global mRNA-based Vaccines and Therapeutics Market Report

• According to DelveInsight’s analysis, the market size for global mRNA-based vaccines and therapeutics across the 7MM is expected to grow with a significant CAGR by 2032.
• According to the American Cancer Society (2023), in general, about 10–15% of all lung cancers are SCLC, and about 80–85% are NSCLC. In 2023, an estimated 238K adults (117K men and 120K women) in the United States will be diagnosed with lung cancer.
• Leading mRNA-based vaccines and therapeutics companies such as Vertex Pharmaceuticals Incorporated, ReCode Therapeutics, ModernaTX, Inc., Merck Sharp & Dohme LLC, Remix Therapeutics, Audentes Therapeutics, Pfizer, Sirnaomics, Phoenicis Therapeutics, Astellas Pharma US, Inc., Immorna Biotherapeutics, Inc., ICON plc, Sangamo Therapeutics, 2seventy bio, Hillhurst Biopharmaceuticals, Inc., Silence Therapeutics plc, STORM Therapeutics LTD, BioNTech SE, Agomab Therapeutics NV, Alnylam Pharmaceuticals, Janssen Pharmaceutica N.V., AstraZeneca, Ocugen, Merus N.V., Sanofi, Immunomic Therapeutics, and others are developing novel mRNA-based vaccines and therapeutics that can be available in the global mRNA-based vaccines and therapeutics market in the coming years.
• The promising global mRNA-based vaccines and therapeutics in the pipeline include VX-522, RCT1100, mRNA-4157, REM-422, scAAV9.U7.ACCA, PF-06651600, STP705, PTW-002 10, Enzalutamide, JCXH-221, BIVV003, bbT369, HBI-002, SLN124, STC-15, BNT112, AGMB-129, ALN-HSD, JNJ-55308942, AZD8701, BBV152, MCLA-158, SAR441000, ITI-1000, and others.

Discover which therapies are expected to grab the major global mRNA-based vaccines and therapeutics market share @ Global mRNA-based Vaccines and Therapeutics Market Report

Global mRNA-based Vaccines and Therapeutics Overview

Messenger RNA (mRNA) is a form of single-stranded ribonucleic acid generated through transcription from a DNA strand. It contains the essential coding information for protein synthesis, which undergoes further transcription and processing to yield functional proteins. The progression of mRNA-based therapeutics encompasses critical stages such as mRNA design, synthesis, mRNA encapsulation, pharmacodynamics, pharmacokinetics, safety assessments in both in vivo and in vitro settings, manufacturing, and clinical trials. The design and synthesis of mRNA stand out as pivotal stages in the development of mRNA-based medications. The therapeutic application of mRNA holds significant promise in addressing a diverse range of incurable diseases. Recent rapid advancements in biotechnology and molecular medicine have empowered the ability to produce nearly any functional protein or peptide within the human body by introducing mRNA as a vaccine or therapeutic agent. This burgeoning field of precision medicine holds considerable potential for preventing and treating numerous challenging or genetic diseases.

Global mRNA-based Vaccines and Therapeutics Epidemiology Segmentation

The global mRNA-based vaccines and therapeutics epidemiology section provides insights into the historical and current global mRNA-based vaccines and therapeutics patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The global mRNA-based vaccines and therapeutics market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Incident Cases of Shortlisted Indications for mRNA Therapy for Oncology
• Total Indication-wise Eligible Cases for mRNA Therapy for Oncology
• Indication-wise Treated Cases of mRNA Therapy for Oncology

Request for sample report @ https://www.delveinsight.com/sample-request/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market

Global mRNA-based Vaccines and Therapeutics Treatment Market

Immunotherapy represents a groundbreaking approach in the field of cancer treatment. The use of mRNA vaccines has become an appealing and potent method for immunotherapy against cancer due to their high effectiveness, specificity, adaptability, ability for rapid and large-scale development, cost-effective manufacturing potential, and safety. Recent advancements in the design and delivery of mRNA vaccines have expedited their development and application in cancer treatment. Extensive research conducted in preclinical and clinical trials has paved the way for the swift progress of mRNA vaccines, particularly evident during the COVID-19 pandemic. These therapeutic cancer vaccines, based on mRNA, are well-received, and the inherent advantage of easy production, comparable to the best traditional vaccine manufacturing methods, positions mRNA vaccines as a promising avenue for cancer immunotherapy.

In 1996, the initial investigation of a cancer vaccine based on mRNA involved testing dendritic cells loaded with RNA in a laboratory setting. Since then, advancements in technology have enhanced the structure, stability, and delivery techniques of mRNA. Currently, numerous clinical trials are actively recruiting cancer patients to explore the efficacy of mRNA-based vaccine therapies. The administration routes for mRNA vaccines encompass intradermal, subcutaneous, intranasal, intranodal, intramuscular, intratumoral, and intravenous delivery.

The majority of cancer vaccines based on mRNA focus on treating existing cancer rather than preventing it, necessitating multiple doses and a significant vaccine strength to elicit a response against tumors when used as the sole form of treatment. While standalone mRNA vaccines may prove effective in treating early-stage cancer or as an additional therapy, their success as a solitary treatment for advanced cancers seems improbable due to the formidable challenges posed by the highly immunosuppressive tumor microenvironment in such cases.

To know more about mRNA-based vaccines and therapeutics, visit @ Global mRNA-based Vaccines and Therapeutics

Pipeline mRNA-based Vaccines and Therapeutics and Key Companies

• VX-522: Vertex Pharmaceuticals Incorporated
• RCT1100: ReCode Therapeutics
• mRNA-4157: ModernaTX, Inc./Merck Sharp & Dohme LLC
• REM-422: Remix Therapeutics
• scAAV9.U7.ACCA: Audentes Therapeutics
• PF-06651600: Pfizer
• STP705: Sirnaomics
• PTW-002 10: Phoenicis Therapeutics
• Enzalutamide: Astellas Pharma US, Inc.
• JCXH-221: Immorna Biotherapeutics, Inc./ICON plc
• BIVV003: Sangamo Therapeutics
• bbT369: 2seventy bio
• HBI-002: Hillhurst Biopharmaceuticals, Inc.
• SLN124: Silence Therapeutics plc
• STC-15: STORM Therapeutics LTD
• BNT112: BioNTech SE
• AGMB-129: Agomab Therapeutics NV
• ALN-HSD: Alnylam Pharmaceuticals
• JNJ-55308942: Janssen Pharmaceutica N.V.
• AZD8701: AstraZeneca
• BBV152: Ocugen
• MCLA-158: Merus N.V.
• SAR441000: Sanofi
• ITI-1000: Immunomic Therapeutics

Learn more about the FDA-approved mRNA-based vaccines and therapeutics @ mRNA-based Vaccines and Therapeutics Analysis

Global mRNA-based Vaccines and Therapeutics Market Dynamics

The dynamics of the global mRNA-based vaccines and therapeutics market are expected to change in the coming years. Several mRNA-based vaccine candidates currently in pre-clinical and clinical phases of development are poised to drive the mRNA-based vaccines and therapeutics market in upcoming years, as the field of mRNA-based therapeutics spans from protein replacement therapy and gene editing to vaccination, and continued advancements in mRNA formulation and delivery using different nanomaterials hold the potential to improve the wider use of mRNA for the treatment and prevention of infectious diseases and cancers.

Furthermore, many potential therapies are being investigated for the treatment of various cancers, and it is safe to predict that the treatment space will significantly impact the global mRNA-based vaccines and therapeutics market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the global mRNA-based vaccines and therapeutics market in the 7MM.

However several factors may impede the growth of the global mRNA-based vaccines and therapeutics market. The broader utilization of mRNA-based therapeutics remains constrained by the requirement for enhanced vectors or drug delivery systems, as advanced delivery systems are essential to address issues such as poor stability, cell targeting, and translational efficiency of naked mRNA. Consequently, challenges persist in the delivery of mRNA-based therapeutics, including technical obstacles that need to be overcome for the successful implementation of mRNA-based therapies.

Moreover, global mRNA-based vaccines and therapeutics treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the global mRNA-based vaccines and therapeutics market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the global mRNA-based vaccines and therapeutics market growth.

Global mRNA-based Vaccines and Therapeutics Market Report Metrics

• Study Period: 2019–2032
• Coverage: 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].
• Key mRNA-based Vaccines and Therapeutics Companies: Vertex Pharmaceuticals Incorporated, ReCode Therapeutics, ModernaTX, Inc., Merck Sharp & Dohme LLC, Remix Therapeutics, Audentes Therapeutics, Pfizer, Sirnaomics, Phoenicis Therapeutics, Astellas Pharma US, Inc., Immorna Biotherapeutics, Inc., ICON plc, Sangamo Therapeutics, 2seventy bio, Hillhurst Biopharmaceuticals, Inc., Silence Therapeutics plc, STORM Therapeutics LTD, BioNTech SE, Agomab Therapeutics NV, Alnylam Pharmaceuticals, Janssen Pharmaceutica N.V., AstraZeneca, Ocugen, Merus N.V., Sanofi, Immunomic Therapeutics, and others
• Key Pipeline mRNA-based Vaccines and Therapeutics: VX-522, RCT1100, mRNA-4157, REM-422, scAAV9.U7.ACCA, PF-06651600, STP705, PTW-002 10, Enzalutamide, JCXH-221, BIVV003, bbT369, HBI-002, SLN124, STC-15, BNT112, AGMB-129, ALN-HSD, JNJ-55308942, AZD8701, BBV152, MCLA-158, SAR441000, ITI-1000, and others

Scope of the Global mRNA-based Vaccines and Therapeutics Market Report

• Therapeutic Assessment: Global mRNA-based Vaccines and Therapeutics current marketed and emerging therapies
• Global mRNA-based Vaccines and Therapeutics Market Dynamics: Key Market Forecast Assumptions of Emerging Global mRNA-based Vaccines and Therapeutics Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Global mRNA-based Vaccines and Therapeutics Market Access and Reimbursement

Discover more about mRNA-based vaccines and therapeutics in development @ mRNA-based Vaccines and Therapeutics Clinical Trials

Table of Contents

1. Global mRNA-based Vaccines and Therapeutics Key Insights

2. Global mRNA-based Vaccines and Therapeutics Report Introduction

3. Global mRNA-based Vaccines and Therapeutics Overview at a Glance

4. Global mRNA-based Vaccines and Therapeutics Executive Summary

5 Global mRNA-based Vaccines and Therapeutics Key Events

6. Epidemiology and Market Forecast Methodology (Disease Background and Overview)

7. Global mRNA-based Vaccines and Therapeutics Treatment and Management

8. Global mRNA-based Vaccines and Therapeutics Guidelines

9. Global mRNA-based Vaccines and Therapeutics Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Global mRNA-based Vaccines and Therapeutics

12. Global mRNA-based Vaccines and Therapeutics Marketed Drugs

13. Global mRNA-based Vaccines and Therapeutics Emerging Drugs

14. 7MM Global mRNA-based Vaccines and Therapeutics Market Analysis

15. Market Access and Reimbursement

16. KOL Views

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/regulatory-analysis-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Global mRNA-based Vaccines and Therapeutics Market is expected to Grow at a decent CAGR during the Study Period (2019-2032) | DelveInsight

“Sleep Tech Devices Market”

(Albany, USA) DelveInsight’s Sleep Tech Devices Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, sleep tech devices market drivers, barriers, and trends, and key sleep tech devices companies in the market.

The sleep tech devices market is expected to boost positively due to factors such as an ageing population, an increase in the prevalence of sleep disorders such as insomnia and narcolepsy, and an increase in the development of technologically advanced sleep tech devices. As a result, the sleep tech devices market is expected to rise at a considerable CAGR from 2024 to 2030.

Request for sample report @ Sleep Tech Devices Market Insights

Key Takeaways from the Sleep Tech Devices Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global sleep tech devices market during the forecast period.
• Key sleep tech devices companies such as Koninklijke Philips N.V, Huawei Device Co Ltd, ResMed, Xiaomi, Apple Inc, ASUSTeK Computer Inc, SAMSUNG, Masimo, Garmin Ltd, Compumedics Limited, NIHON KOHDEN CORPORATION, Cadwell Industries Inc, Eight Sleep, Emfit Ltd, Ōura Health, Sleep Shepherd LLC, Sleepace, Apollo Neuroscience Inc, Braebon Medical Corporation, Noise, and several others are currently dominating the sleep tech devices market.
• On October 28, 2024, Neurovalens, a prominent health-tech company, launched Modius Sleep, a groundbreaking device aimed at treating chronic insomnia. This innovative product utilizes non-invasive neurostimulation technology to enhance sleep quality by targeting specific neurons in the brain responsible for regulating sleep patterns.
• On September 30, 2024, ResMed, a health technology company, a new collection of patient-centric digital solutions designed to enhance the management of sleep apnea. This launch includes innovative products that integrate artificial intelligence and digital wearables to improve patient engagement and health outcomes.
• On June 13, 2024, Wakefit, a company that offers home solutions, particularly in sleep products, launched Wakefit Zense range, an AI-powered sleep solutions, in India. It includes Regul8 and Track8 where former is a mattress temperature controller which manages the surface temperature of the mattress, while latter is a contactless sleep tracker.
• In February 2024, ResMed launched its AirCurve 11 series devices. These devices use two levels of support, inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), combined with digital technology to make it easier for healthcare providers to treat sleep apnea and to help patients start and stay on therapy. This product launch may help the company to gain a competitive edge over its peers.
• In October 2023, Fisher & Paykel Healthcare Corporation Limited announced the launch of the F&P Solo mask in New Zealand and Australia for the treatment of obstructive sleep apnea (OSA). Without conventional straps to undo and pull, the mask reduces overtightening on the face. This product launch helped the company to increase its product range and acquire an enhanced customer base.
• In June 2022, Garmin, a Swiss-domiciled multinational technology company, launched its Vivosmart 5 fitness band in India, with health features such as it comes with advanced sleep monitoring (with sleep stages).
• In June 2022, pTron, an Indian electronics manufacturer, announced the launch of a new smartwatch in India: the Force X10E, which includes features such as sleep monitoring.
• In June 2022, Amazefit, a smart wearable brand, launched GTS 2 smartwatch with some special features such as sleep monitoring in India.

To read more about the latest highlights related to the sleep tech devices market, get a snapshot of the key highlights entailed in the Global Sleep Tech Devices Market Analysis

Sleep Tech Devices Overview

Sleep tech devices are innovative tools designed to monitor, analyze, and improve sleep quality using advanced technologies. These devices cater to individuals struggling with sleep disorders, such as insomnia or sleep apnea, and those seeking to optimize their sleep for better health and productivity.

Sleep tech includes wearable devices like smartwatches and fitness trackers, non-wearable options such as bedside monitors or smart mattresses, and therapeutic devices like CPAP machines for sleep apnea. Wearables typically measure metrics like sleep duration, stages (light, deep, REM), heart rate, and movement through sensors. Non-wearables use motion detection, sound analysis, or biometrics to provide insights into sleep patterns without direct contact.

Some devices integrate with apps to offer personalized recommendations, guided relaxation techniques, or alarms optimized for waking during lighter sleep stages. Advanced systems use artificial intelligence (AI) to provide actionable insights and adaptive feedback based on individual sleep data.

These devices are beneficial for identifying sleep issues, tracking progress over time, and promoting better sleep hygiene. However, while sleep tech enhances awareness, it is not a substitute for professional medical advice. Combining these tools with healthy sleep habits and consulting healthcare providers for persistent issues ensures the most effective sleep improvement strategies.

Sleep Tech Devices Market Insights

North America is predicted to lead the global sleep tech devices market in 2021, and it is expected to do so again during the forecast period of 2024-2030. Factors such as the rising frequency of sleep disorders such as narcolepsy, as well as an increase in the launch of technologically advanced sleep tech devices in the United States, are projected to drive demand for sleep tech devices in the North American sleep tech devices market. Furthermore, the region’s spike in the launch of technologically enhanced sleep tech devices will drive the sleep tech devices market.

As a result, the interaction of the factors described above for sleep tech devices would produce a favourable growth environment for the North American region in the sleep tech devices market.

To know more about why North America is leading the market growth in the sleep tech devices market, get a snapshot of the report Sleep Tech Devices Market Outlook

Sleep Tech Devices Market Dynamics

The growing geriatric population is one of the primary drivers of the sleep tech devices market. Another important reason driving the growth of the sleep tech devices market is the rising prevalence of insomnia globally. Furthermore, organisations such as the National Sleep Foundation, World Sleep Society, Brazilian Sleep Society, Italian Association of Sleep Medicine, and others educate people all over the world about sleep and related diseases.

However, the privacy hazards offered by sleep-tracking devices and home sleep tech devices are likely to produce false-positive results and are not 100% accurate, hampering the global sleep tech devices market expansion.

Additionally, the ongoing COVID-19 pandemic has substantially impacted the sleep tech devices market. The manufacturing of sleep tech gadgets was hampered by a statewide lockdown in practically every country, mobility restrictions for non-essential commodities, and a lack of labour at the production facilities. However, sleep issues appear to have been widespread during the ongoing COVID-19 pandemic, which has been linked to a high degree of psychological distress, which can enhance the likelihood of sleep disorders. As a result, the COVID pandemic might have greatly impacted the sleep tech devices market. Sleep tech devices are predicted to develop further throughout the forecast period, as are mass vaccinations, relaxation of lockdown limitations, and the restart of supply networks, logistics, and industrial units.

Get a sneak peek of the Sleep Tech Devices market @ Sleep Tech Devices Market Trends

Scope of the Sleep Tech Devices Market Report

• Coverage: Global
• Study Period: 2024–2030
• Market Segmentation By Type: Wearables and Non Wearables
• Market Segmentation By Application: Obstructive Sleep Apnea, Central Sleep Apnea, Insomnia, Narcolepsy, and Others
• Market Segmentation By End User: Hospitals, Home-Care Settings, and Others
• Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Key Sleep Tech Devices Companies: Koninklijke Philips N.V, Huawei Device Co Ltd, ResMed, Xiaomi, Apple Inc, ASUSTeK Computer Inc, SAMSUNG, Masimo, Garmin Ltd, Compumedics Limited, NIHON KOHDEN CORPORATION, Cadwell Industries Inc, Eight Sleep, Emfit Ltd, Ōura Health, Sleep Shepherd LLC, Sleepace, Apollo Neuroscience Inc, Braebon Medical Corporation, Noise, among others
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
• DelveInsight Analysis: The Sleep Tech Devices market size is expected to grow at a CAGR of 17.31% during the forecast period (2024–2030).

Which key players in the sleep tech devices market are set to emerge as the trendsetter explore @ Sleep Tech Devices Companies and Advancements

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Sleep Tech Devices Market

7. Sleep Tech Devices Market Layout

8. Global Company Share Analysis – Key 3-5 Companies

9. Company and Product Profiles

10. Project Approach

11. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Global Sleep Tech Devices Market to Grow at a Significant CAGR of ~17% by 2030, etimates DelveInsight

“Cancer Biomarkers Market”

(Albany, USA) DelveInsight’s Cancer Biomarkers Market Insights report provides the current and forecast market analysis, individual leading cancer biomarkers companies’ market shares, challenges, cancer biomarkers market drivers, barriers, and trends, and key cancer biomarkers companies in the market.

The cancer biomarkers market is experiencing positive market growth as a result of an increase in the prevalence of various types of cancers worldwide, a growing population with risk factors for cancer development such as smoking and a high-fat diet, among others, and increased research and development activities in the cancer biomarkers arena leading to new product launches and increasing regulatory approvals, which are expected to result in appreciable revenue growth.

Request for sample report @ Cancer Biomarkers Market Insights

Key Takeaways from the Cancer Biomarkers Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global cancer biomarkers market during the forecast period.
• Notable cancer biomarkers companies such as F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., and several others are currently operating in the cancer biomarkers market.
• In August 2024, Illumina received approval from the USFDA for its cancer biomarkers test.
• In May 2024, Lantern Pharma entered into an agreement with Oregon in order to utilize the former’s RADR AI platform to streamline the development process of XCE853.
• In April 2024, Denovo Biopharma received USD 11.8 million from the California Institute for Regenerative Medicine to advance the development of DB107, a late-stage gene therapy for the treatment of glioblastoma.
• In March of 2023, LES LABORATOIRES SERVIER partnered with QIAGEN to create a novel mIDH1 companion diagnostic test to advance their Hemato-Oncology Portfolio. This collaboration focuses on developing a test to identify acute myeloid leukemia patients.
• In January 2023, Lunit, in collaboration with Guardant Health, announced the integration of its AI-based PD-L1 scoring algorithm into Guardant’s testing workflow to improve biomarker detection in the Guardant360 TissueNextTM PD-L1 test for non-small cell lung cancer (NSCLC).
• In November 2022, EDX Medical Group plc, which develops innovative digital diagnostic products and services for cancer, heart disease, neurology, and infectious disease testing, announced a collaborative cancer biomarker program that will improve access to cost-effective and reliable tests for a variety of cancers in the United Kingdom and Europe.
• In September 2022, AstraZeneca, an Anglo-Swedish pharmaceutical company, and Roche, a Swiss company, announced a collaboration to redefine cancer diagnosis and treatment in the Middle East and North Africa. The collaboration aims to remove barriers to biomarker testing and expand access to precision medicines in a region where cancer is expected to double by 2030.
• In August 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance to a blood-based biomarker assay for disease monitoring in patients with metastatic breast cancer (MBC). The Divitum Tka assay, developed by Biovica International AB in Uppsala, Sweden, measures the activity of the enzyme thymidine kinase-1 (TK1), which is linked to cell proliferation and is a predictor of tumor aggressiveness. It is the first FDA-approved liquid cancer cell proliferation biomarker assay for monitoring metastatic breast cancer.
• In February 2022, OncoDNA, a genomic and theranostic company, announced the launch of OncoDeep kit, integrating both reagents and quality control standards for the sequencing of over 600 cancer biomarkers, which provide powerful data analysis and support oncologists in the most effective and personalized treatments for cancer patients.

To read more about the latest highlights related to the cancer biomarkers market, get a snapshot of the key highlights entailed in the Global Cancer Biomarkers Market Report

Cancer Biomarkers Overview

Cancer biomarkers are biological molecules that aid in the detection of cancer in patients. They are produced by either cancer cells or non-cancer cells in response to the onset and progression of cancer. They can be identified from serum and used for personalized daily care in screening, diagnosis, prognosis, treatment monitoring, and detecting relapse. Despite advances in cancer treatment, some people do not respond to traditional chemotherapy treatment paradigms or experience disease recurrence. Biomarkers are becoming more important in the clinical care of cancer patients as genomic profiling technologies and selective molecular targeted therapies advance.

The use of biomarkers in cancer treatment has changed the course of treatment dramatically. For decades, many cancers were treated in the same way: with surgery, radiation therapy, or chemotherapy. The identification of biomarkers in cancer cells has resulted in the development of novel precision medicine treatments, such as targeted therapy and immunotherapy, which are designed to target specific traits in cancer cells while causing minimal harm to healthy cells.

Cancer Biomarkers Market Insights

North America dominated the global cancer biomarkers market in 2022 and will continue to do so through the forecast period (2024–2030). This dominance is due to the rising prevalence of various types of cancers in North America. Furthermore, product development activities such as gaining regulatory approvals is expected to boost the North American cancer biomarkers market during the forecast period. For instance, in August 2022, the US Food and Drug Administration (FDA) granted 510(k) clearance to a blood-based biomarker assay for disease monitoring in patients with metastatic breast cancer (MBC). The Divitum Tka assay, developed by Biovica International AB in Uppsala, Sweden, measures the activity of the enzyme thymidine kinase-1 (TK1), which is linked to cell proliferation and is a predictor of tumor aggressiveness. It is the first FDA-approved liquid cancer cell proliferation biomarker assay for monitoring metastatic breast cancer.

To know more about why North America is leading the market growth in the cancer biomarkers market, get a snapshot of the Cancer Biomarkers Market Outlook

Cancer Biomarkers Market Dynamics

One of the major factors driving the growth of the cancer biomarkers market is the global increase in the prevalence of various types of cancer. As per the data cited by the World Health Organization 2022, worldwide, around 2.26 million cases of breast cancer, 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, and 1.09 million cases of stomach cancer were reported in 2020. Because of the large number of cancer patients worldwide, diagnostic and prognostic procedures and research and development activities are expected to increase significantly, boosting market demand for cancer biomarkers during the forecast period (2024–2030).

However, certain technical issues related to sample collection and storage, high costs incurred in R&D activities, limited infrastructural facilities, and others may act as restraints on the growth of the cancer biomarkers market.

Get a sneak peek at the cancer biomarkers market dynamics @ Cancer Biomarkers Market Dynamics Analysis

Cancer Biomarkers Market Assessment

• Coverage: Global
• Cancer Biomarkers Market CAGR: ~14%
• Key Cancer Biomarkers Companies: F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others
• Cancer Biomarkers Market Segmentation

• Market Segmentation By Type: Protein, Genetic, and Others
• Market Segmentation By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, and Others
• Market Segmentation By Technology: Omics, Imaging, Immunoassay, and Others
• Market Segmentation By Application: Diagnostics, Drug Delivery, Prognostics, and Others
• Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the cancer biomarkers market are set to emerge as the trendsetter explore @ Cancer Biomarkers Companies

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Cancer Biomarkers Market

7. Cancer Biomarkers Market Layout

8. Global Company Share Analysis – Key 3-5 Companies

9. Cancer Biomarkers Market Company and Product Profiles

10. Project Approach

11. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Global Cancer Biomarkers Market to Upsurge at a Tremendous CAGR of ~14% by 2030, estimates DelveInsight

“Myopia Treatment Devices Market”

(Albany, USA) According to the latest report published by DelveInsight “Myopia Treatment Devices Market Insight,” the global Myopia Treatment Devices Market is anticipated to witness stellar growth owing to the rising government initiatives to raise awareness among the population regarding myopia treatment, increase in myopia affected cases across the globe, rise in product launches of various advanced myopia management devices. This report will provide an in-depth understanding of the Myopia Treatment Devices market which will further benefit the competitors or stakeholders operating in the Myopia Treatment Devices market.

The Myopia Treatment Devices market is anticipated to boost as the demand for these devices is increasing at a considerable rate owing to the rising prevalence of myopia, worldwide. Additionally, an increase in the adoption rate of Myopia Treatment Devices is further expected to bolster the global market for Myopia Treatment Devices during the forecast period (2024-2030).

Request for sample report @ Myopia Treatment Devices Market Insight

Key Takeaways from the Myopia Treatment Devices Market Report

• As per DelveInsight estimates, APAC is anticipated to dominate the global Myopia Treatment Devices market during the forecast period.
• The leading Myopia Treatment Devices companies such as CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark’ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others are currently working in the Myopia Treatment Devices market.
• In January 2024, Eyenovia, Inc., a commercial-stage, ophthalmic company, announced that it has re-acquired the rights to MicroPine in the U.S. and Canada. MicroPine, an investigational eight microliter ophthalmic spray of atropine delivered by Eyenovia’s proprietary Optejet device, is being evaluated as a potential treatment for pediatric progressive myopia which is characterized by elongation of the sclera/retina.
• In October 2023, NIDEK CO LTD launched the NP-1/NP-1C Preloaded IOL Injection System. The NP-1/NP-1C is a fully preloaded injection system with an aspheric hydrophobic soft acrylic lens designed for smoother, safer, and secure IOL implantation. This newly developed injector is designed for smooth, controlled delivery. The NP-1/NP-1C allows quick and easy operation using a simple two-step process involving, filling the viscoelastic material and pressing the plunger.
• On May 25, 2021, CooperVision DreamLite® Ortho-K Lenses gained European approval for slowing the progression of myopia.
• On May 12, 2021, Euclid Systems Corporation, a global leader in advanced orthokeratology and proactive myopia management, launched the latest breakthrough in overnight orthokeratology lens, Euclid MAX in the US.
• On April 07, 2021, Menicon entered into a global collaboration with Johnson & Johnson Vision to bring forward therapeutic contact lens-related products and services to manage the progression of myopia in children.
• Thus, owing to such developments in the market, there will be rapid growth observed in the Myopia Treatment Devices market during the forecast period.

To read more about the latest highlights related to Myopia Treatment Devices, get a snapshot of the key highlights entailed in the Myopia Treatment Devices Market Report

Myopia Treatment Devices

Myopia, or near-sightedness is a refractive vision disorder that causes blurred sight at a distance. It occurs when the length of the eye (known as axial length) is too great; myopia progresses as axial length increases with age. The devices such as eyeglasses, contact lenses, and Ortho-K lenses, among others which are used to slow down the progression of myopia are termed myopia treatment devices.

Children who are at high risk of progressive myopia (due to a family history of the condition, early age of onset, and lengthy durations of close work) may benefit from treatment options that have been found to slow the advancement of myopia. These treatments for myopia include bifocal spectacle or contact lens prescription, orthokeratology, eye drops, or a combination of these. Myopia control may assist protect eye health since those with extreme myopia are more likely to develop cataracts, glaucoma, and myopic macular degeneration.

Learn more about the treatment of myopia @ Best Treatment for Myopia

Myopia Treatment Devices Market Insights

Geographically, the global Myopia Treatment Devices market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. APAC is projected to witness the fastest growth during the study period. This is owing to the rising prevalence of the targeted population. Moreover, rising government initiatives to raise awareness regarding the proper management of myopia among the population in the region is also a potential factor for Myopia Treatment Devices market growth.

Furthermore, the presence of regional companies such as Menicon Co., Ltd., Kubota Pharmaceutical Holdings Co., Ltd., among others, and their increased focus on developing novel Myopia treatment options will also contribute to the fastest Myopia Treatment Devices market growth in the region. For instance, Kubota Pharmaceutical Holdings Co., Ltd. with its subsidiary Kubota Vision is planning to use the Kubota Glass technology which leverages nanotechnology in an electronic glasses-based device to reduce the progression of myopia by actively stimulating the retina for shorter periods while maintaining high-quality central vision and not affecting daily activities to develop smart contact lenses for the reduction of myopia progression.

To know more about why APAC is leading the market growth in the Small Myopia Treatment Devices market, get a snapshot of the report Myopia Treatment Devices Market

Myopia Treatment Devices Market Dynamics

The Myopia Treatment Devices market is gaining pace at present owing to the growing myopia cases across the globe. Furthermore, approval of various myopia treatment devices in various countries across the globe to slow down the progression of the disease is also projected to augment the Myopia Treatment Devices market in the upcoming years. For instance, on June 03, 2020, SightGlass Vision achieved CE Mark allowing European Marketing Authorization for novel eyeglasses that slow myopia progression in children. The spectacles developed by the company comprise advanced diffusion optics technology spectacle lenses. Hence, the above-mentioned factors are expected to increase the Myopia Treatment Devices market in the future.

However, limitations associated with the refractive surgery procedures and stringent regulatory approval process for the myopia treatment devices are likely to impede the growth of the Myopia Treatment Devices market.

Moreover, the unprecedented COVID-19 impact had sluggish the Myopia Treatment Devices market growth. This is due to the implementation of stringent lockdowns across the nation, and the reduction in clinic visits due to reluctance among patients during the pandemic, among others. However, a sudden shift toward digital or e-learning approaches from classroom-based learning has subsequently increased myopia and its progression among the students. For instance, as per the report published by UNESCO in the year 2020, approximately 1.37 billion students from more than 130 countries globally were affected by the pandemic as the schools and universities adopted digital learning during the pandemic to curb the infection.

Thus, it is expected to increase the risk of myopia among the children which will increase the demand for the myopia treatment devices during the post-pandemic situation, thus the Myopia Treatment Devices market will gain normalcy.

Get a sneak peek at the Myopia Treatment Devices market dynamics @ Myopia Treatment Devices Market Dynamics Analysis

Scope of the Myopia Treatment Devices Market Report

• Coverage: Global
• Study Period: 2021-2030
• Market Segmentation By Treatment – Corrective Lenses, Laser Eye Surgery, Lens Implant Surgery
• Market Segmentation By Product Type – Eyeglasses, Contact Lenses, Ortho-K Lenses, Phakic Intraocular Lenses, Excimer Laser Refractive Surgery Devices
• Market Segmentation By End-User – Hospitals, Specialty Clinics, and Others
• Market Segmentation By Geography – North America, Europe, Asia-Pacific, and Rest of World
• Key Myopia Treatment Devices Companies – CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark’ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, among others
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

DelveInsight Analysis: The Myopia Treatment Devices market size is expected to grow at a CAGR of 7.57% during the study period (2021-30).

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Myopia Treatment Devices Market

7. Myopia Treatment Devices Market Layout

8. Global Company Share Analysis – Key 3-5 Companies

9. Myopia Treatment Devices Market Company and Product Profiles

10. Project Approach

11. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myopia Treatment Devices Market is expected to Grow at a CAGR of 7.57% During the Study Period (2021-30), estimates DelveInsight

“Dental Implants and Prosthesis Market”

(Albany, USA) DelveInsight’s Dental Implants and Prosthesis Market Insights and Forecast report provides the current and forecast Dental Implants and Prosthesis, upcoming innovations in the devices, individual market shares of the devices, challenges, drivers, and barriers, market trends, and key competitors in the Dental Implants and Prosthesis Market scenario.

The Dental Implants and Prosthesis market is witnessing positive growth owing to the growing burden of the geriatric population who are susceptible to developing various dental disorders, the rising prevalence of various dental diseases due to poor eating habits, lack of oral hygiene, and accidents that cause tooth loss across the globe. In addition, accumulative focus on developing technologically advanced devices in the product arena are some of the factors contributing to the Global Dental Implants and Prosthesis Market.

Request for sample report @ Dental Implants and Prosthesis Market

Some of the essential takeaways from the Dental Implants and Prosthesis Market report:

• According to DelveInsight analysis, North America is expected to dominate the overall Dental Implants and Prosthesis Market during the forecasted period.
• Key Dental Implants and Prosthesis companies proactively working in the market include Fresenius SE & Co. KgaA, Boston Scientific Corporation, Cook Medical, Inc., Cardinal Health Inc., Becton, Dickinson, and Company, Moog Inc., B. Braun Melsungen AG, Amsino International, Inc., Nestlé Health Science, Avanos Medical, Inc., Abbott Laboratories, CONMED Corporation, CORPAK, Covidien PLC, ALCOR Scientific Inc., Applied Medical Technology, Inc., Vygon, Danone, Enteral Access Technologies Ltd., Medline Industries, LP, among others.
• The dental implants and prosthesis market was valued at USD 9.67 billion in 2023, growing at a CAGR of 7.79% during the forecast period from 2024 to 2030 to reach 15.16 billion by 2030.
• On January 17, 2022, Renew, LLC and Western Dental & Orthodontics entered into a strategic partnership to make high-quality implant-supported removable anchored dentures surgical centers in California and Texas.
• On January 17, 2022, Yomi, a robot-assisted surgical device developed by the healthcare start-up Neocis, gained FDA clearance for general dental implant procedures in 2016 and full-arch dental implant procedures in 2020. Since its development, Yomi has become increasingly popular, and its manufacturer has recently announced that clinicians have already placed over 10,000 dental implants using the dental robotic platform.
• On June 08, 2021, Neoss announced the launch of NeossONE™. NeossONE™ is a solution unique to the Neoss® Implant System – one prosthetic platform, across three implant ranges, including ALL implant diameters and abutments.

To pick on the latest highlights related to Enteral Feeding Procedures get the snapshot of the key highlights entailed in the Dental Implants and Prosthesis Market Forecast

Dental Implants and Prosthesis Overview

Dental implants and prostheses are advanced solutions for replacing missing teeth, restoring oral function, aesthetics, and overall quality of life. A dental implant is a titanium or zirconia post surgically placed into the jawbone, serving as an artificial tooth root. Over time, the implant integrates with the bone through a process called osseointegration, providing a stable foundation for various prosthetic options.

Prostheses attached to implants include crowns, bridges, and dentures. Single-tooth implants support individual crowns, while multiple implants can anchor bridges or full-arch dentures. Implant-supported prostheses are highly durable, mimic natural teeth, and prevent bone resorption often associated with tooth loss.

The process typically involves an initial consultation, diagnostic imaging, and treatment planning, followed by surgical placement, healing, and prosthesis attachment. Advances in digital dentistry, such as 3D imaging and guided surgery, have improved accuracy and success rates.

Dental implants offer several advantages, including improved chewing efficiency, speech, and confidence. While traditional dentures or bridges may be less costly upfront, implants are a more durable and functional long-term solution. However, they may not suit everyone due to factors like insufficient bone density, medical conditions, or financial considerations, necessitating a tailored approach to each patient’s needs.

Dental Implants and Prosthesis Market Insight

Geographically, the Global Dental Implants and Prosthesis market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America is expected to dominate the overall Dental Implants and Prosthesis market during the forecast period. This domination is owing to the rising burden of the geriatric population in the region suffering from dental disorders, the rising prevalence of various dental diseases such as edentulism, and technologically advanced devices in the product arena will bolster the growth of the North America Dental Implants and Prosthesis market.

Furthermore, the presence of key manufacturers such as Nobel Biocare Services AG (Danaher Corporation), Straumann Holding AG, Dentsply Sirona, among others active in the production of Dental Implants and Prosthesis is anticipated to fuel the market in the region. Moreover, the occurrence of various strategic business activities in the region such as company collaborations, acquisitions, product launches, and approval, among others are also expected to propel the market for Dental Implants and Prosthesis in the region.

Learn more about the Several Types of Dental Implants and Prosthesis @ Dental Implants and Prosthesis Market Assessment

Dental Implants and Prosthesis Market Dynamics

Owing to certain factors such as the growing burden of the geriatric population who are susceptible to developing various dental disorders, the rising prevalence of various dental diseases due to poor eating habits, lack of oral hygiene, and accidents that causes tooth loss across the globe are some of the factors likely to boost the Dental Implants and Prosthesis market. In addition, accumulative focus on developing technologically advanced devices in the product arena will contribute a lot to the Global Dental Implants and Prosthesis Market. Furthermore, Dental Implants and Prosthesis have become an important tool, as they are minimally invasive surgical procedures for dental and cosmetic applications, and the rising adoption of computer-aided design/computer-aided manufacturing (CAD/CAM) technologies for implants have led to producing simplified and accurate implants components, all the aforementioned factors are expected to augment the global market for Dental Implants and Prosthesis.

However, the high cost of the implants and some of the dental treatments which are not covered under health coverage is likely to impede the Dental Implants and Prosthesis market. Also, the unprecedented COVID-19 pandemic has had a substantial effect on the Dental Implants and Prosthesis Market

To gain a better understanding of the impact of drivers and barriers on Dental Implants and Prosthesis, get a snapshot of the Dental Implants and Prosthesis Market Impact

Scope of the Dental Implants and Prosthesis Market Report

• Coverage: Global
• Study Period: 2021-2030
• Dental Implants and Prosthesis companies: Fresenius SE & Co. KgaA, Boston Scientific Corporation, Cook Medical, Inc., Cardinal Health Inc., Becton, Dickinson, and Company, Moog Inc., B. Braun Melsungen AG, Amsino International, Inc., Nestlé Health Science, Avanos Medical, Inc., Abbott Laboratories, CONMED Corporation, CORPAK, Covidien PLC, ALCOR Scientific Inc., Applied Medical Technology, Inc., Vygon, Danone, Enteral Access Technologies Ltd., Medline Industries, LP, among others.
• Market Segmentation By Material: Titanium Implants, Zirconium Implants
• Market Segmentation By Design: Tapered Dental Implants, Parallel-Walled Dental Implants
• Market Segmentation By Types: Endosteal Implants, Subperiosteal Implants, Others
• Market Segmentation By Prosthesis/Products: Dentures, Crown, Bridges, Veneer, Abutment, Inlays & Onlays
• Market Segmentation By End-User: Hospitals, Dental Clinics, Others
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View
• Dental implants and prosthesis market was valued at USD 9.67 billion in 2023, growing at a CAGR of 7.79% during the forecast period from 2024 to 2030 to reach 15.16 billion by 2030.

Know more about which MedTech player is set to dominate the Dental Implants and Prosthesis market @ Key Dental Implants and Prosthesis Companies

Table of Contents

1. Report Introduction

2. Executive summary

3. Regulatory and Patent Analysis

4. Dental Implants and Prosthesis Market Key Factors Analysis

5. Dental Implants and Prosthesis Market Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Dental Implants and Prosthesis Market

7. Dental Implants and Prosthesis Market Layout

8. Dental Implants and Prosthesis Market Global Company Share Analysis – Key 3-5 Companies

9. Dental Implants and Prosthesis Company and Product Profiles

10. Project Approach

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dental Implants and Prosthesis Market is Expected to Grow at a CAGR of ~8% by 2030, Analyzes DelveInsight

“Spinal Cord Injury Drugs Market”

(Albany, USA) DelveInsight’s Spinal Cord Injury Market Insights report includes a comprehensive understanding of current treatment practices, spinal cord injury emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

The spinal cord injury (SCI) market is driven by increasing incidence rates, advancements in regenerative medicine, and the growing adoption of neurostimulation devices. Rising cases due to accidents, falls, and sports injuries fuel demand for innovative treatment options. Emerging therapies, including stem cell research, gene therapy, and exoskeleton technologies, are reshaping the landscape. However, challenges such as high treatment costs, limited curative options, and regulatory hurdles restrain market growth. Key players focus on developing novel therapies and rehabilitation solutions to improve patient outcomes. As research advances, the SCI market is expected to witness steady growth, offering new hope for patients.

Request for sample report @ Spinal Cord Injury Market Insights

Key Takeaways from the Spinal Cord Injury Market Report

• As per DelveInsight analysis, the spinal cord injury market is expected to grow positively at a significant CAGR during the study period (2020–2034).
• In March 2025, Phantom Neuro, a neurotech company advancing human-machine interfaces, announced that it has received two prestigious designations from the U.S. Food and Drug Administration (FDA): the Breakthrough Device Designation and the highly selective TAP (Targeted Acceleration Pathway) Designation for its minimally invasive neural interface, the Phantom X platform.
• In February 2025, Neuvotion Receives FDA Clearance for NeuStim™ Providing Non-Invasive, High-Resolution Stimulation for the Hand After Stroke or Spinal Cord Injury
• March 2024: Mitsubishi Tanabe Pharma America Inc. announced a study of Phase 2 clinical trials for MT-3921. The purpose of this study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury. Subjects meeting eligibility criteria will enter the 6-month double-blind period. Subjects will be randomized in a 2:1 ratio to receive MT-3921 or placebo in a double blind manner.
• March 2024: Moleac Pte Ltd announced a study of Phase 4 clinical trials for NeuroAiD. SATURN investigates the promising role of NeuroAiD in patients with spinal cord injury and will provide important information on the feasibility of conducting larger controlled trials.
• March 2024: NervGen Pharma announced a study of Phase 1 & 2 clinical trials for NVG-291. To evaluate the effect of NVG-291 on descending connectivity in subjects with subacute and chronic SCI (20 subjects per Cohort and results will be analyzed separately) using objective electrophysiological measures, in addition to clinical assessments. To evaluate safety and tolerability of NVG-291 in a SCI population, as measured by clinical assessments (Physical Examination, Vital Signs, ECG, etc.) as well as clinical laboratory measures.
• As per the DelveInsight assessment, the total diagnosed cases of SCI in the 7MM was estimated to be ~725K cases in 2022, which is expected to increase in the forecast period (2022-2034).
• Leading spinal cord injury companies such as NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others are developing novel spinal cord injury drugs that can be available in the spinal cord injury market in the coming years.
• Some key therapies for spinal cord injury treatment include NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others.

Discover which therapies are expected to grab the major spinal cord injury market share @ Spinal Cord Injury Market Report

Spinal Cord Injury Overview

Spinal cord injury is a debilitating condition resulting from trauma or disease that damages the spinal cord, impairing motor, sensory, and autonomic functions below the level of injury. Common causes include motor vehicle accidents, falls, sports injuries, and medical conditions like tumors or infections. Spinal cord injury can be classified as complete, with total loss of function, or incomplete, where some sensation or movement remains.

The severity of Spinal cord injury depends on the location and extent of damage. Injuries to the cervical spine can result in quadriplegia, affecting all four limbs, whereas injuries to the thoracic, lumbar, or sacral regions typically cause paraplegia, involving the lower body.

Spinal cord injury Symptoms vary widely and may include paralysis, loss of sensation, pain, spasticity, and autonomic dysfunction affecting bladder, bowel, and cardiovascular regulation. Acute Spinal cord injury is a medical emergency requiring immediate stabilization to prevent further damage.

Spinal cord injury Treatment focuses on minimizing damage and promoting recovery. Initial care includes immobilization, corticosteroids to reduce inflammation, and surgical intervention when needed. Long-term management involves physical rehabilitation, occupational therapy, and assistive technologies to improve independence. Advances in regenerative medicine, including stem cell therapy, neuroprosthetics, and electrical stimulation, offer hope for improving outcomes and quality of life for individuals with Spinal cord injury.

Spinal Cord Injury Epidemiology Segmentation

The spinal cord injury epidemiology section provides insights into the historical and current spinal cord injury patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The spinal cord injury market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Spinal Cord Injury Cases
• Spinal Cord Injury Diagnosed Cases
• Spinal Cord Injury Gender-specific Cases
• Spinal Cord Injury Cause-specific Cases
• Total cases of SCI at Neurological Level

To know more about spinal cord injury treatment, visit @ Spinal Cord Injury Treatment Drugs

Spinal Cord Injury Treatment Market

In the initial care of a patient with a spinal cord injury, the foremost priority is to establish and secure the airway, ensure proper breathing, and maintain circulation. This is followed by the crucial step of immobilizing the spine in the field to prevent any further harm to the vulnerable spinal cord during transportation. It is of paramount importance to recognize and triage SCI patients appropriately in the early stages to guarantee the prompt delivery of specialized treatments at dedicated centers.

While maintaining spinal immobilization, airway, and breathing management can vary from administering supplemental oxygen to performing intubation and providing mechanical ventilation. At any stage during the initial injury, the presence of systemic hypotension (defined as a systolic blood pressure [SBP] of less than 90 mmHg) is correlated with poorer neurological outcomes. Profound loss of vascular tone and the possibility of bradycardia can lead patients to quickly progress into neurogenic shock. The primary treatment approach revolves around administering large volumes of intravenous (IV) fluids, primarily crystalloids. However, healthcare providers may also opt to use additional alpha-adrenergic vasopressor medications such as norepinephrine and phenylephrine to temporarily stabilize patients.

Currently, there is no consensus on the optimal methods for diagnosing and treating different aspects of spinal cord injuries. This lack of agreement is partly a result of the diversity in injury patterns (cervical versus thoracic, complete versus incomplete) and contradictory interpretations of available literature.

Key Spinal Cord Injury Therapies and Companies

• NVG-291: NervGen Pharma
• Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
• Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc.
• MT-3921: Mitsubishi Tanabe Pharma America Inc.
• Elezanumab: AbbVie

Learn more about the FDA-approved drugs for spinal cord injury @ Drugs for Spinal Cord Injury Treatment

Spinal Cord Injury Market Dynamics

The dynamics of the spinal cord injury market are expected to change in the coming years. Both academic institutions and industries are actively pursuing advanced approaches to the development of innovative therapies. Recent advancements in comprehending the pathophysiology of spinal cord injuries have triggered a notable increase in clinical trials. Continuous dedication to basic and clinical research is forging a new path toward regenerative medicine in SCI. Nevertheless, the lack of an efficient therapy to target SCI-related symptoms and complications remains a pressing issue.

Furthermore, many potential therapies are being investigated for the treatment of spinal cord injury, and it is safe to predict that the treatment space will significantly impact the spinal cord injury market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the spinal cord injury market in the 7MM.

However, several factors are impeding the growth of the spinal cord injury market. Many researchers maintain a sense of skepticism and caution regarding the practicality of stem cell therapies. The pricing and accessibility issues surrounding these treatments continue to be a significant point of contention. A substantial portion of clinical trials has fallen short of achieving their intended outcomes, often due to a lack of understanding of the disease’s underlying causes and suboptimal trial designs. The early approval of stem cell-based treatments can lead to patients opting for experimental therapies, which may carry risks and prove ineffective, placing a heavy financial burden on both patients and insurance providers.

Moreover, spinal cord injury treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the spinal cord injury market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the spinal cord injury market growth.

Scope of the Spinal Cord Injury Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
• Key Spinal Cord Injury Companies: NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others
• Key Spinal Cord Injury Therapies: NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, MT-3921, Elezanumab, and others
• Therapeutic Assessment: Spinal Cord Injury current marketed and emerging therapies
• Spinal Cord Injury Market Dynamics: Conjoint Analysis of Emerging Spinal Cord Injury Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Spinal Cord Injury Market Access and Reimbursement

Discover more about spinal cord injury drugs in development @ Spinal Cord Injury Clinical Trials

Table of Contents

1. Spinal Cord Injury Market Key Insights

2. Spinal Cord Injury Market Report Introduction

3. Spinal Cord Injury Market Overview at a Glance

4. Spinal Cord Injury Market Executive Summary

5. Disease Background and Overview

6. Spinal Cord Injury Treatment and Management

7. Spinal Cord Injury Epidemiology and Patient Population

8. Patient Journey

9. Spinal Cord Injury Marketed Drugs

10. Spinal Cord Injury Emerging Drugs

11. Seven Major Spinal Cord Injury Market Analysis

12. Spinal Cord Injury Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Cord Injury Drugs Market 2034: Clinical Trials, Medication, EMA, PDMA, FDA Approval, Epidemiology, Therapies and Companies by DelveInsight